Home > News > BioSante Presents CaP-adjuvanted Bird Flu Vaccine Data
May 23rd, 2006
BioSante Presents CaP-adjuvanted Bird Flu Vaccine Data
Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that Dr. Steve Bell, vice president of research and pre-clinical development, presented a case study highlighting the potential of BioVant(TM), the Company's calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, in influenza virus vaccines, including H5N1 avian influenza, or bird flu.
Source:
businesswire
Related News Press |
Nanomedicine
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
SMART researchers pioneer first-of-its-kind nanosensor for real-time iron detection in plants February 28th, 2025
Announcements
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |